ONLINE EDUCATION IMPROVES NEUROLOGISTS’ KNOWLEDGE OF INVESTIGATIONAL THERAPIES FOR THE TREATMENT OF MULTIPLE SCLEROSIS

Thomas P. Finnegar, MD, MBA, James Delano, MD, and Stephen Kruger, MD
Medscape, LLC, New York, NY; Icahn School of Medicine at Mount Sinai, New York, New York

INTRODUCTION

Despite the availability of many disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS), there is universally continue option remains elusive. Several investigational therapies for MS are in late-stage clinical trials, but whether these therapies will be successful in improving knowledge, results from the educational intervention launched online was designed with the goal of improving neurologists’ knowledge of investigational DMTs for the treatment of MS.

ASSESSMENT METHOD

The study design compared each participant’s responses to questions posed before exposure to educational content (pre-assessment measurement) with the same participants’ responses to questions after exposure to the educational content (post-assessment measurement).

CONCLUSIONS

The use of an online video-based lecture as a means of educating neurologists was effective in improving knowledge, results from the educational intervention launched online was designed with the goal of improving neurologists’ knowledge of investigational DMTs for the treatment of MS.

INSTRUCTIONAL METHOD

The online educational activity was presented as a 3-minute video lecture with synchronized slides. Interactive questions with immediate feedback were inserted in the activity to encourage learner engagement and assess knowledge or competence.4

RESULTS

A total of 101 neurologists who participated in the activity and completed the post-assessment questions were included in the data analysis (Figure 2). After completing the activity, there was a 61% increase in the percentage of neurologists who made evidence-based choices compared with the percentage who made these choices prior to the activity.

REFERENCES


FIGURE 1. Linked Learning Assessment

FIGURE 2. Percentage of Participants With Correct Response by Question

A. Correct response by question

B. Summary statistics

FIGURE 3. Question 1

FIGURE 4. Question 2

FIGURE 5. Question 3

FIGURE 6. Question 4

Acknowledgment: The study was supported in part by grants from the following organizations: Biogen Idec, Genentech, Novartis, and Teva Pharmaceutical Industries.